SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending following an unsolicited bid to acquire eBay in a multi-billion dollar cash-and-stock deal, sparking intense community debate over potential share dilution versus the strategic vision of transforming into a broader e-commerce platform. Investors are expressing skepticism regarding financing and the viability of the deal, while many community members remain focused on the potential for a massive short squeeze driven by retail momentum.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending as a key beneficiary of the ongoing AI infrastructure build-out, with the community actively debating whether the company has transitioned from a cyclical memory player to a structural AI hardware leader. Investors are closely monitoring high-conviction analyst price targets and significant demand for HBM that has caused supply shortages, leading to widespread discussion about the sustainability of the stock's parabolic climb.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is currently surging due to a combination of heavy short interest and positive momentum, leading investors to speculate on an impending short squeeze ahead of upcoming earnings. The community is focused on high borrow rates and limited share availability, fueling bullish sentiment despite broader market volatility.

Xanadu Quantum Technologies Ltd. engages in the provision of quantum computing solutions for enterprise and government customers. The company was founded by Christian Weedbrook on October 2, 2025 and is headquartered in Toronto, Canada.

Xanadu Quantum Technologies Ltd. - Ordinary Shares - Class B (Sub Voting)

Xanadu Quantum Technologies is experiencing extreme volatility and intense community debate following a share resale registration that investors are interpreting as either a massive dilution event or a standard unlock of existing shares. While some traders are aggressively buying the dip, banking on the company's photonic technology and potential government contracts, others are labeling the recent price action as a classic pump-and-dump scheme and warning of significant downward pressure.

CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. Its product pipeline includes berubicin, and CNS-12. The company was founded by Waldemar Priebe in July 2017 and is headquartered in Houston, TX.

Cns Pharmaceuticals Inc

CNS Pharmaceuticals is experiencing significant market interest driven by an oversubscribed private placement that investors are interpreting as validation for its new strategic focus on neurology and oncology. The community is actively debating the stock's extreme volatility and low float, with many participants focused on potential short-squeeze dynamics and the impact of the company's shift toward acquiring clinical-stage assets.

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded in 2013 and is headquartered in Salt Lake City, UT.

Clene Inc

Clene Inc. is currently a focal point for investors as the community anticipates critical upcoming data regarding biomarker analysis and potential FDA accelerated approval pathways for its ALS candidate, CNM-Au8. Discussion is heavily focused on the company's regulatory roadmap, the impact of recent insider selling, and the broader context of how emerging biomarker evidence could influence the stock's long-term valuation.

eBay, Inc. is a commerce company, whose platforms include an online marketplace and its localized counterparts, including off-platform businesses in South Korea, Japan, and Turkey, as well as eBay’s suite of mobile apps. It offers a platform for various product categories, including parts and accessories, collectibles, fashion, electronics, and home & garden. eBay generates revenue mainly through fees from sales, payment processing, and advertising. The company was founded by Pierre Morad Omidyar in September 1995 and is headquartered in San Jose, CA.

EBay Inc.

eBay Inc

eBay is trending following an unsolicited takeover proposal from GameStop, which has fueled intense community debate over the feasibility of the deal and the potential for a massive acquisition strategy. Market participants are actively scrutinizing the financing requirements and the viability of a cash-and-stock offer that significantly exceeds GameStop's current market valuation.

High-Trend International Group is a holding company. It engages in shipping decarbonization and carbon asset management platforms. The company was founded in 2021 and is headquartered in Singapore.

High-Trend International Group. - Ordinary Shares - Class A

HTCO is experiencing significant volatility driven by heavy short interest and a low-float structure, with community discussions largely centered on aggressive short squeeze potential and speculative trading dynamics. Investors are debating the sustainability of the price action, frequently drawing parallels to past momentum plays while others warn of the risks associated with rapid, news-sparse price swings.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is trending as investors digest the recent strategic acquisition of Eigen AI and monitor the broader AI infrastructure buildout. Market participants are actively debating the company's valuation against sector peers, the impact of hyperscaler capital expenditure cycles, and the potential for a technical breakout or short squeeze following recent price action.

Federal National Mortgage Association is a government-sponsored company, which engages in the provision of liquidity for purchases of homes and financing of multifamily rental housing and refinancing existing mortgages. It operates through the Single-Family and Multifamily segments. The Single-Family segment offers liquidity to the mortgage market and increases the availability and affordability of housing for single families. The Multifamily segment includes guaranty fees on mortgages and on multifamily mortgage loans. The company was founded in 1938 and is headquartered in Washington, DC.

Federal National Mortgage Association

Fannie Mae shares are rallying as the community reacts to high-profile bullish sentiment from prominent investors, fueling intense speculation about a potential end to conservatorship. Investors are actively discussing the possibility of a major policy catalyst and a subsequent IPO, leading to significant trading volume and a sentiment shift focused on the stock's long-term valuation potential.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Best Value Stocks to Buy for May 28th

New Strong Buy Stocks for May 28th

Shares of Phio Pharmaceuticals Corp. (PHIO) traded 63% higher on Wednesday after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://phiopharma.com/phio-pharmaceuticals-announces-positive-safety-monitoring-committee-recommendation-to-advance-intasyl-ph-762-skin-cancer-study-to-fourth-dose-escalation-cohort/">announced</a> that a Safety Monitoring Committee (SMC) recommended escalating the dose in the clinical trial for its lead product candidate, PH-762.The dose-escalating clinical trial aims to evaluate the safety and tolerability of neoadjuvant use of intratumoral PH-762 in certain skin cancers. The trial assesses tumor response and determines the recommended dose for further study of the product candidate.PH-762 is an Intasyl compound that silences the PD-1 gene implicated in various forms of skin cancer.CEO Robert Bitterman said the company is optimistic the clinical trial will continue to demonstrate that PH-762 may present a viable non-surgical alternative to existing modes of therapy for skin cancer.The company said that two of four patients diagnosed with cutaneous squamous cell carcinoma and enrolled in the second cohort of the trial had 100% tumor clearance upon excision.While one had a 90% tumor clearance, the fourth patient maintained stable disease, the company said.Three patients were enrolled in the third cohort of the trials. The injections were well tolerated with no serious adverse events, the company said.On Stocktwits, retail sentiment around Phio Pharmaceuticals rose from ‘bearish’ to ‘extremely bullish’ while message volume jumped from ‘high’ to ‘extremely high’ over the past 24 hours.<figure class="image"><img style="aspect-ratio:1298/298;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_09_at_1_47_54_PM_png_f2666fba4f.webp" alt="PHIO's Sentiment Meter and Message Volume as of 2:00 p.m. ET on April 9, 2025 | Source: Stocktwits" width="1298" height="298"><figcaption>PHIO's Sentiment Meter and Message Volume as of 2:00 p.m. ET on April 9, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/PHIO">PHIO shares</a> rose as high as $2.73 on Wednesday before paring gains to around $1.50.The stock fell by over 13% this year and by over 73% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/pacbio-plans-to-reduce-spending-over-nih-funding-uncertainty-tariffs/chfnXrfRbBd">PacBio Stock Soars On Plans To Reduce Spending Over NIH Funding Uncertainty, Tariffs: Retail Is Overjoyed</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Phio Pharmaceuticals Stock Soars On Clearance To Escalate Dose In Skin Cancer Treatment Trial: Retail’s Thrilled

CEO Robert Bitterman said the company is optimistic that the clinical trial will continue to demonstrate that PH-762 may present a viable non-surgical alternative to existing modes of therapy for skin cancer. 

Equity

CEO Robert Bitterman said the company is optimistic that the clinical trial will continue to demonstrate that PH-762 may present a viable non-surgical alternative to existing modes of therapy for skin cancer.

Shares of Phio Pharmaceuticals Corp. (PHIO) nearly&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/phio-stock-rockets-on-cancer-trial-data/chGNgCORNj">quadrupled</a> on Monday after the biotech firm announced promising results from its Phase 1b trial for the cancer immunotherapy PH-762, designed to enhance the immune system's ability to target tumors.However, the nanocap stock reversed course on Tuesday, plunging over 50% following news of a registered direct offering.Phio revealed agreements to sell 1.1 million common shares at $3 each, with a concurrent private placement issuing short-term warrants to purchase 2.1 million shares at the same price.&nbsp;The combined transactions are expected to generate approximately $3.2 million in gross proceeds, earmarked for working capital and other corporate purposes.Despite the sharp decline, retail investors remain optimistic, as evidenced by a Stocktwits poll where nearly 50% of over 900 participants believe the stock has "more room to run."&nbsp;Around 34% foresee a pullback, while 13% are uncertain due to the stock's volatility.Retail sentiment on Stocktwits turned 'extremely bullish' on Tuesday, with many users predicting a post-offering rally fueled by Phio's low float and the potential of its drug pipeline.&nbsp;Some highlighted the company's ongoing trial progress, while others saw the price drop as a buying opportunity.<stembedurl>https://stocktwits.com/pragash2094/message/599992949</stembedurl><stembedurl>https://stocktwits.com/HUBC1/message/599986181</stembedurl><stembedurl>https://stocktwits.com/TrendIsMyFriend/message/599998502</stembedurl>Like many early-stage biotech firms, Phio has yet to generate revenue. However, its latest financial report showed narrowed losses of $1.5 million for the quarter ended Sept. 30, compared to $2.8 million a year earlier.&nbsp;The company reported $5.4 million in cash, down from $8.4 million a year earlier but more than $4.7 million at the end of the previous quarter.The stock has lost nearly 50% of its value over the past year but has seen retail interest soar. The number of new followers on Stocktwits jumped by over 9%, while message volume increased more than 1,600-fold.With a short interest of 3.8% and ongoing developments in its PH-762 trial, retail investors remain laser-focused on updates about higher-dose concentrations and further enrollment milestones.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Phio’s stock has lost nearly 50% of its value over the past year but has seen retail interest soar. | Image source: Maria Korneeva on Getty Images

We Asked Retail What's Next For Phio Pharma After Monday's Blistering Rally: Most See More Room To Run

Around 34% foresee a pullback, while 13% are uncertain due to the stock's volatility.

Shares of Phio Pharmaceuticals Corp. surged 330% Monday afternoon, reaching their highest levels in nearly eight months, to become the top gainer across U.S. bourses.&nbsp;This explosive move followed the announcement of positive results from a Phase 1b trial of its cancer treatment, PH-762, which is designed to enhance the immune system’s ability to target tumors.&nbsp;Trading volume soared to over 220 times the daily average, drawing significant attention from retail investors.Phio revealed that patients in the second cohort of its ongoing trial exhibited these pathologic responses: Two patients with cutaneous squamous cell carcinoma experienced a complete response (100% tumor clearance); one patient had a partial response (90% tumor clearance); one patient maintained stable disease, with no progression.The trial focuses on evaluating PH-762 for neoadjuvant use in Stages 1, 2, and 4 cutaneous squamous cell carcinoma, Stage 4 melanoma, and Stage 4 Merkel cell carcinoma.&nbsp;Importantly, no dose-limiting toxicities or clinically relevant adverse events have been reported, and the intratumoral injections have been well tolerated, the company said.Mary Spellman, Acting chief medical officer of Phio, expressed optimism about the tumor responses, saying, “We look forward to continued enrollment which will permit assessment of higher dose concentrations of PH-762.”&nbsp;"These positive results in the early stages of dose escalation offer promise for our vision, 'striving for a cancer free future' using INTASYL technology" said CEO Robert Bitterman.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/PHIO_sentiment_meter_and_message_volume_Jan_13_38cb5ff222.png" alt="PHIO sentiment meter and message volume Jan 13.png" width="1318" height="324"><figcaption>PHIO sentiment meter and message volume Jan 13 as of 12:15 pm ET | source: Stocktwits</figcaption></figure>On Stocktwits, sentiment for Phio spiked to 'extremely bullish' levels, with users sharing optimistic price targets and success stories.<stembedurl>https://stocktwits.com/M105/message/599814732</stembedurl><stembedurl>https://stocktwits.com/Ian980/message/599806765</stembedurl><a href="https://stocktwits.com/symbol/PHIO">Phio’s stock</a> has gained nearly 15% over the past 12 months, with Monday’s rally marking a sharp shift in momentum.&nbsp;Investors are closely watching for further enrollment updates and results from higher dose concentrations in the ongoing trial.For updates and corrections, email newsroom[at]stocktwits[dot]com.

The trial focuses on evaluating PH-762 for neoadjuvant use in Stages 1, 2, and 4 cutaneous squamous cell carcinoma, Stage 4 melanoma, and Stage 4 Merkel cell carcinoma. | Image source: Getty Images

Phio Pharma Stock Quadruples On Positive Data From Cancer Treatment Trial: Retail’s Elated

CEO Robert Bitterman highlighted the potential of Phio’s proprietary INTASYL RNAi technology, which targets proteins that hinder the body’s immune response to cancer.

Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA.

PHIO
Phio Pharmaceuticals Corp

Feed

News

Sentiment

Fundamentals

Info

Historical Earnings

Latest PHIO News

PHIOPhio Pharmaceuticals Corp